Skip to main content
NVSEF logo

Novartis AG (NVSEF) Stock Price & Analysis

Novartis AG (NVSEF) — price $156.50 (-1.85%), as of the Nov 19, 2026 trading session; market cap $296B.

Educational signal · not a buy or sell recommendation · How to read this

$156.50 −$2.95 (-1.85%) Market Cap $296B

Novartis AG · NVSEF · Healthcare · Drug Manufacturers - General

Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): Novartis spans innovative prescription medicines, generics, biosimilars, active ingredients and biotechnology manufacturing services rather than relying on a uniform drug portfolio. Its case rests on whether broad commercial reach and sustained research spending can keep expanding profit and cash generation while debt remains far above liquid resources.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • MRK · Merck & Co., Inc. · 69 /100
  • AMGN · Amgen Inc. · 84 /100
  • GILD · Gilead Sciences, Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$156.50
Change on the day-1.85%
52-week range$123.69–$171.29
Market capitalisation$296B—
Price / earnings (trailing)30.47
Shares traded on the day20
Beta (volatility vs the S&P 500)0.49

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $120, high $171, latest $157. $171 $120 high $171 Oct 17, 2025 Nov 19, 2026 · $157 $131Oct 17, 2025$128Oct 31, 2025$127Nov 14, 2025$132Nov 28, 2025$127Dec 12, 2025$138Dec 26, 2025$138Jan 9, 2026$152Jan 23, 2026$153Feb 6, 2026$162Feb 20, 2026$163Mar 6, 2026$150Mar 20, 2026$155Apr 2, 2026$151Apr 17, 2026$147May 1, 2026$143May 15, 2026$145May 29, 2026$145Jun 12, 2026$153Jun 26, 2026$154Jul 10, 2026$154Jul 24, 2026$152Aug 7, 2026$158Aug 21, 2026$164Sep 4, 2026$134Sep 18, 2026$134Oct 2, 2026$144Oct 16, 2026$160Oct 30, 2026$162Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Novartis AG (NVSEF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Moderate
Debt/Equity Weak
ROE Strong
Gross Margin Strong

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Novartis AG (NVSEF), and what does it report?

Short answer · as of

Novartis researches, develops, manufactures and commercializes medicines worldwide.

Innovative Medicines serves patients and healthcare professionals across areas including neuroscience, immunology, cardiovascular, renal and metabolic disease, while Sandoz supplies generics, biosimilars, anti-infectives, active ingredients and manufacturing services to external partners.

2 · Latest results

What do the latest results show for Novartis AG (NVSEF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $14.11B.

Revenue, gross profit, operating profit, net income and diluted earnings all improved from the immediately preceding period, but remained below the comparable earlier period. The rebound therefore reached well beyond sales and appeared clearly in operating and net profit.

The latest earnings release cleared analyst expectations for revenue and earnings after a mixed sequence of beats and misses. On the annual view, revenue and net income advanced while research spending also increased, showing that recent profit growth did not require a retreat from development investment.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$14.11B$1.17B$0.61 (diluted)
Q2 FY2026$14.09B$3.19B$1.67 (diluted)
Q1 FY2026$12.86B$3.09B$1.62 (diluted)
Q4 FY2025$13.44B$2.43B$1.26 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Novartis AG (NVSEF)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow stayed positive throughout the displayed run and comfortably exceeded capital expenditure in the latest period. Trailing margins and free-cash-flow yield reinforce the picture of a profitable, cash-generative pharmaceutical operation.

Debt substantially exceeds cash and investments, short-term coverage ratios remain below full coverage, and cash has fallen materially across the reported window despite a recent recovery. Weaker prescription demand would therefore meet substantial research and commercial spending alongside a meaningful debt burden, reducing room for error even while current cash generation remains strong.

4 · What to check next?

What should you watch next at Novartis AG (NVSEF)?

At the next release, watch whether revenue and earnings clear consensus while operating profit and operating cash flow preserve their latest rebound. Cash also needs monitoring against debt: stabilization would strengthen the financial picture, while renewed erosion would make the leverage gap harder to dismiss.

Consensus assumes revenue and earnings continue rising across the forecast horizon. Stagnant sales, weaker profit conversion or heavier cash use would conflict with that trajectory; continued growth paired with resilient cash generation would support it.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is Novartis AG scored?

Novartis combines the economics of an innovative-medicine developer with activities more typical of a generic and biosimilar supplier. It also produces finished-dose medicines, active ingredients and intermediates for external partners and offers biotechnology manufacturing services, so consolidated revenue blends patented prescription products with broader pharmaceutical supply and service activity.

That operating breadth differs from a pure research-led drug developer and from a pure generic producer. The financial profile still carries the heavy research commitment and high margins associated with innovative pharmaceuticals, while the balance sheet adds leverage that a comparison based only on product breadth would miss.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Roche Holding AG (RHHBF) Named competitor$485.00 Nov 19, 2026$386B— Model unavailable
AstraZeneca PLC (AZNCF) Named competitor$189.90 Sep 25, 2026$294B— Model unavailable
GSK plc (GLAXF) Named competitor$24.45 Nov 18, 2026$98.0B— Model unavailable
Sartorius Stedim Biotech S.A. (SRTOY) Named competitor$24.44 Nov 19, 2026$23.8B— Model unavailable
Novo Nordisk A/S (NONOF) Named competitor$39.50 Nov 19, 2026$174B— Model unavailable
Merck & Co., Inc. (MRK) Same industry, near in market value$137.78 Nov 18, 2026$340B— 5-pillar · not comparable
Amgen Inc. (AMGN) Same industry, near in market value$443.89 Nov 18, 2026$240B— 5-pillar · not comparable
Gilead Sciences, Inc. (GILD) Same industry, near in market value$168.98 Nov 18, 2026$210B— 5-pillar · not comparable
AbbVie Inc. (ABBV) Same industry, near in market value$286.01 Nov 18, 2026$506B— 5-pillar · not comparable
Pfizer Inc. (PFE) Same industry, near in market value$28.06 Nov 18, 2026$160B— 5-pillar · not comparable
Johnson & Johnson (JNJ) Same industry, near in market value$272.70 Nov 18, 2026$656B— 5-pillar · not comparable
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$58.34 Nov 19, 2026$119B— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NVSEF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported NVSEF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Novartis AG (NVSEF)?

Read these with our analysis →

NVSEF Healthcare Stock FAQ

The last question is answered from this page's own dated data, not from the research.

What does Novartis sell beyond Innovative Medicines?

Sandoz supplies generic and biosimilar medicines, anti-infectives, active ingredients and intermediates, while also providing biotechnology manufacturing services to external partners.

How does Sandoz change the way Novartis revenue should be read?

Consolidated revenue reflects more than advanced prescription medicines. It also includes finished-dose generics, biosimilars, pharmaceutical ingredients and manufacturing services, giving Novartis a broader demand base than a pure innovative-drug developer.

Does Novartis generate cash while funding its research base?

Operating cash flow remained positive across the displayed periods and exceeded capital expenditure, while annual research spending increased alongside revenue and net income. Cash generation is therefore substantial, although debt remains well above liquid resources.

What does the Alnylam inclisiran collaboration add to Novartis?

The agreement covers development, production and commercialization of inclisiran, extending Novartis through a partnered medicine rather than an internally controlled program alone.

What is the NVSEF stock price today?

The last price recorded for Novartis AG (NVSEF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 1 from SEC filings and earnings calls, 16 from Financial Modeling Prep (FMP) and 1 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is Novartis AG (NVSEF), and what does it report?: Business description; Sector / industry (provider taxonomy); Employees
  • 2. What do the latest results show for Novartis AG (NVSEF)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Novartis AG (NVSEF)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set
  • 4. What should you watch next at Novartis AG (NVSEF)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt
  • 5. How is Novartis AG scored?: Business description; Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Cash, investments and debt
  • FAQ: What does Novartis sell beyond Innovative Medicines?: Business description
  • FAQ: How does Sandoz change the way Novartis revenue should be read?: Business description; Sector / industry (provider taxonomy)
  • FAQ: Does Novartis generate cash while funding its research base?: Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Cash, investments and debt; Trailing twelve-month ratio set
  • FAQ: What does the Alnylam inclisiran collaboration add to Novartis?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.